Cargando…

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes

BACKGROUND: Gliomas evade current therapies through primary and acquired resistance and the effect of temozolomide is mainly restricted to methylguanin‐O6-methyltransferase promoter (MGMT) promoter hypermethylated tumors. Further resistance markers are largely unknown and would help for better strat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessler, Tobias, Berberich, Anne, Sadik, Ahmed, Sahm, Felix, Gorlia, Thierry, Meisner, Christoph, Hoffmann, Dirk C., Wick, Antje, Kickingereder, Philipp, Rübmann, Petra, Bendszus, Martin, Opitz, Christiane, Weller, Michael, van den Bent, Martin, Stupp, Roger, Winkler, Frank, Brandes, Alba, von Deimling, Andreas, Platten, Michael, Wick, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666733/ https://www.ncbi.nlm.nih.gov/pubmed/32991787 http://dx.doi.org/10.1002/cam4.3447

Ejemplares similares

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

Automated brain extraction of multisequence MRI using artificial neural networks
por: Isensee, Fabian, et al.
Publicado: (2019)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
por: Wick, A., et al.
Publicado: (2022)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
por: Coomans, Marijke B, et al.
Publicado: (2022)

Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting
por: Eidel, Oliver, et al.
Publicado: (2016)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma
por: Panitz, Verena, et al.
Publicado: (2021)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
por: Kudo, Takumi, et al.
Publicado: (2020)

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
por: Coomans, Marijke B, et al.
Publicado: (2019)

Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients
por: Coomans, Marijke B, et al.
Publicado: (2020)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

Conventional and emerging treatments of astrocytomas and oligodendrogliomas
por: Kessler, Tobias, et al.
Publicado: (2022)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Treatment of glioblastoma in adults
por: Wick, Wolfgang, et al.
Publicado: (2018)

Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling
por: Coomans, Marijke B, et al.
Publicado: (2020)

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
por: Caramanna, Ivan, et al.
Publicado: (2022)

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
por: Litzenburger, Ulrike M., et al.
Publicado: (2014)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps
por: Reimer, Caroline, et al.
Publicado: (2017)

DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma
por: Adeberg, Sebastian, et al.
Publicado: (2022)

Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging
por: Abu Sammour, Denis, et al.
Publicado: (2023)

Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology
por: Eidel, Oliver, et al.
Publicado: (2017)

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2020)

Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2022)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5kqui2ua1u7eclf539vs3t62oo